Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients HIV positive \> 18 years.~* Patients in treatment with Sustiva(r)+Truvada(r); or Sustiva (r)+Kivexa(r).~* HIV-ARN \< 50 copies/mL in the las six months.~* Clinically evident lipoatrophy (moderate or severe).~* Negative pregnancy test.~* Signed informed consent.~Exclusion Criteria:~* Evidence of failure or mutation to therapy with protease inhibitors.~* Patients that can not be treated with LPV/r.~* Mild lipoatrophy.~* History of alcoholism or drug addiction that discourages participation in the study.~* Pregnancy or breastfeeding.~* Documented current or 4 weeks prior opportunistic infection.~* Creatinin clearance \< 60mL/min.~* Concomitant use of nephrotoxic drugs or immunosuppressants.~* Actual treatment with systemic corticosteroids, IL-2 or chemotherapy.~* Patients under treatment with other drugs in investigation.~* Acute hepatitis.~* Any other disease that discourages participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EFV and Fixed combinations of analogues (Type: ACTIVE_COMPARATOR): EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
- LPV/r and combination of analogues. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).